MedTrace Logo

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

NCT01935453 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-09-01

No results posted yet for this study

Summary

The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.

Conditions

Interventions

BIOLOGICAL

Recombinant hGM-CSF Herpes Simplex Virus Injection

Sponsors & Collaborators

  • START Shanghai

    collaborator UNKNOWN

  • Beijing Bozhiyin T&S Co., Ltd.

    collaborator INDUSTRY

  • OrienGene Biotechnology Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin Li, MD · Fudan University

  • Jun Ren, MD · Beijing Shijitan Hospital,CMU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935453 on ClinicalTrials.gov